Skip to main content
. 2020 Oct 15;12(10):975. doi: 10.3390/pharmaceutics12100975
95%CI 95% confidence intervals
B/P blood-to-plasma ratio
CLR renal clearance
fu unbound fraction
IC 50 concentration related to half of the maximal inhibitory concentration
IP intraperitoneal
LSA local sensitivity analysis
PBPK Physiologically based pharmacokinetic
PBPK-PD Physiologically based pharmacokinetic/pharmacodynamic
TGI tumor growth inhibition
Vss volume of distribution at steady state